1. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.

    The Lancet 386(10004):1649 (2015) PMID 26231455

    The thrombopoietin receptor agonist eltrombopag has been shown to be safe, tolerable, and effective for adults with chronic immune thrombocytopenia. We aimed to investigate the safety and efficacy of eltrombopag for children with chronic immune thrombocytopenia. PETIT2 was a two part, randomised...
  2. Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.

    Journal of Gastroenterology and Hepatology 30(8):1301 (2015) PMID 25777337

    Thrombocytopenia is frequently observed in patients with chronic hepatitis C virus (HCV) infection and cirrhosis, although it can also be observed in patients without cirrhosis by a virus-mediated phenomenon. This study assessed the prevalence, characteristics, and outcomes of antiviral therapy ...
  3. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.

    The Lancet. Haematology 2(8):e315 (2015) PMID 26688484

    The oral thrombopoietin receptor agonist eltrombopag is approved for treatment of adults with chronic immune thrombocytopenia. In the PETIT trial, we aimed to investigate the efficacy and safety of eltrombopag in children with persistent or chronic immune thrombocytopenia. PETIT was a three-part...
  4. Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials.

    Circulation: Heart Failure 4(1):18 (2011) PMID 21036889

    The safety and efficacy of different types of β-blocker therapy in patients with non-dialysis-dependent chronic kidney disease (CKD) and systolic heart failure (HF) are not well described. We assessed whether treatment of systolic HF with carvedilol is efficacious and safe in adults with CKD. We...
  5. Effect of combining extended-release carvedilol and lisinopril in hypertension: results of the COSMOS study.

    Journal of Clinical Hypertension 12(9):678 (2010) PMID 20883227

    Hypertension treatment commonly requires multiple agents to achieve target blood pressure (BP). β-blockers and angiotensin-converting enzyme inhibitors (ACEIs) are commonly co-prescribed in clinical practice although few data are available that test their additivity on BP lowering. The efficacy ...
  6. Importance of blood pressure control in left ventricular mass regression.

    Journal of the American Society of Hypertension 4(6):302 (2010) PMID 20980215

    Blood pressure (BP) reduction to 140/90 mm Hg or lower using renin-angiotensin-system blockers reportedly provides the greatest left ventricular (LV) mass regression; β-blockers have less effect. This study examined whether combination antihypertensive therapy would provide greater benefit. With...
  7. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis.

    Journal of Clinical Oncology 27(17):2831 (2009) PMID 19332723 PMCID PMC2698018

    Nonhormonal treatment options have been investigated as treatments for hot flashes, a major clinical problem in many women. Starting in 2000, a series of 10 individual double-blind placebo-controlled studies has evaluated newer antidepressants and gabapentin for treating hot flashes. This curren...
  8. Low doses of controlled-release paroxetine in the treatment of late-life depression: a randomized, placebo-controlled trial.

    Journal of Clinical Psychiatry 70(1):46 (2009) PMID 19026248

    To evaluate the efficacy and tolerability of low daily doses of controlled-release (CR) paroxetine in patients with late-life depression. This was a 10-week, multicenter, placebo-controlled, double-blind, fixed-dose trial randomly assigning patients >or= 60 years old to daily doses of paroxetine...
  9. Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) study.

    Journal of the CardioMetabolic Syndrome 3(4):211 (2008) PMID 19040589

    In the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial, carvedilol added to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers had neutral or beneficial effects on glycemic measures compared with metoprolol tartrate....
  10. Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial.

    Journal of Clinical Hypertension 9(11):842 (2007) PMID 17978591

    The effects of beta-blockade in addition to more specific renin-angiotensin system (RAS) blockers on blood pressure (BP) in patients with diabetes are described. After washout of medications other than angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, patients were titr...
  11. Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension.

    Journal of Clinical Hypertension 8(12):840 (2006) PMID 17170609

    Beta-blockers with pharmacologic effects that differ from conventional agents might add to antihypertensive treatment options. This study evaluated a new once-daily formulation of the beta-/alpha1-blocker, carvedilol controlled-release (CR), in hypertensive patients off treatment or while still ...
  12. Controlled-release carvedilol in the treatment of essential hypertension.

    The American Journal of Cardiology 98(7A):32L (2006) PMID 17023230

    Carvedilol is a beta1-, beta2-, and alpha1-adrenergic blocker that is approved for the treatment of hypertension. A new once-daily, controlled-release (CR) formulation of carvedilol has been shown to be effective in a double-blind, randomized, multicenter, placebo-controlled, parallel-group stud...
  13. Controlled-Release Carvedilol in the Treatment of Essential Hypertension

    The American Journal of Cardiology 98(7):32 (2006)

    Carvedilol is a β 1-, β 2-, and α 1-adrenergic blocker that is approved for the treatment of hypertension. A new once-daily, controlled-release (CR) formulation of carvedilol has been shown to be effective in a double-blind, randomized, multicenter, placebo-controlled, par...
  14. Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database.

    Journal of Clinical Psychiatry 67(1):41 (2006) PMID 16426087

    Paroxetine is a potent selective serotonin reuptake inhibitor with antidepressant and anxiolytic activity that is effective in the treatment of generalized anxiety disorder (GAD), improving the core symptoms of anxiety, worry, and tension. The majority of patients with GAD have chronic symptomat...
  15. The rationale and design of the Glycemic Effects in Diabetes Mellitus:Carvedilol–Metoprolol Comparison in Hypertensives (GEMINI) trial

    Journal of Diabetes and its Complications 19(2):74 (2005)

    β-blockers utilized in the Type 2 diabetic patient result in an even greater decrease in cardiac events than in the nondiabetic patient. Unfortunately, first-and second-generation β-blockers are associated with the worsening of insulin resistance, deterioration of glycemic control, peripher...
  16. The rationale and design of the Glycemic Effects in Diabetes Mellitus Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial.

    Journal of Diabetes and its Complications 19(2):74 (2005) PMID 15745836

    Beta-blockers utilized in the Type 2 diabetic patient result in an even greater decrease in cardiac events than in the nondiabetic patient. Unfortunately, first-and second-generation beta-blockers are associated with the worsening of insulin resistance, deterioration of glycemic control, periphe...
  17. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial.

    JAMA 289(21):2827 (2003) PMID 12783913

    Standard therapy for hot flashes has been hormone replacement with estradiol or progestational agents, but recent data suggest that antidepressants inhibiting serotonin reuptake may also be effective. To evaluate a selective serotonin reuptake inhibitor (paroxetine controlled release [CR]) in tr...
  18. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study.

    American Journal of Psychiatry 160(4):749 (2003) PMID 12668365

    This study assessed the efficacy of two fixed doses of paroxetine in the treatment of generalized anxiety disorder. Outpatients (N=566) with generalized anxiety disorder and no other axis I disorder were eligible if they scored >/=20 on the Hamilton Rating Scale for Anxiety (with a score of 2 or...
  19. Randomized, double-blind study of controlled release paroxetine in treatment of menopausal hot flash

    Obstetrics & Gynecology 101(4):S97 (2003)